Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
Menée sur des patientes atteintes d'un cancer du sein HER2+ de stade précoce, cet essai de phase III évalue l'efficacité, du point de vue du taux de réponse pathologique complète, et la toxicité de l'ajout d'atézolizumab à un traitement néoadjuvant combinant chimiothérapie, pertuzumab et trastuzumab
Approximately 70% of newly diagnosed breast cancers are early-stage, estrogen receptor–positive (ER-positive) and human epidermal growth factor receptor 2–negative (HER2-negative). With optimal adjuvant systemic therapy, including 5-10 years of adjuvant endocrine therapy (ET) with either tamoxifen or an aromatase inhibitor, most patients will be cured, and mortality from breast cancer has declined by over one-third in the past 3 decades.1 However, an unacceptably high percentage of patients with newly diagnosed ER-positive breast cancer will still suffer distant metastatic recurrence and mortality. Those with certain disease characteristics such as axillary lymph node involvement, grade 3 disease, or high genomic risk are at highest risk for disease recurrence, up to 20% at 10 years.
Journal of Clinical Oncology , éditorial, 2021